Keywords
type 2 diabetes mellitus, heart diseases, glucose-lowering therapy.
How to Cite
Yefimov, A., & Sokolova, L. (2012). Glucose-lowering therapy i n patients with type 2 diabetes mellitus and heart diseases. Endokrynologia, 17(4), 23-26. Retrieved from https://endokrynologia.com.ua/index.php/journal/article/view/418
Abstract
The current views on the problem of heart disease and choosing glucose-lowering therapy with the cardioprotective properties of drugs in patients with diabetes are presented.
References
1. UK Prospective Diabetes study Group. Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in T2 DM (UKPDS 33) // Lancet. 1998, 352, 837-853.
2. Gaede P.P., Lund-Andersen H., Parving H.H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes // N. Engl. J. Med. 2008, 358, 580-591.
3. Nathan D.M., Buse J.B., Davidson M.B. et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from ADA and EASD // Diabetes Care. 2008, 31, 1-11.
4. Уніфікований клінічний протокол надання медичної допомоги хворим на ЦД 2 типу, 2012
5. IDF Clinical GuidelinesTask Force. IDF Global Guidelines for type 2 Diabetes, 2005.
6. UK Prospective Diabetes study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with T2 DM (UKPDS 34) // Lancet. 1998, 352, 854-865.
7. Cusi K., De Fronzo R.A. Metformin: a review of its metabolic effect // Diabetes Rev. 1998, 6, 89-131.
8. The ADVANCE Collaborative Group // Engl. J. Med. 2008, 358, 2560-2572.
9. Amori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis // JAMA. 2007, 298, 194–206.
10. Gerstein H.C. et al. The ORIGIN Study // Am. Heart. J. 2008,155, 26-32.
2. Gaede P.P., Lund-Andersen H., Parving H.H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes // N. Engl. J. Med. 2008, 358, 580-591.
3. Nathan D.M., Buse J.B., Davidson M.B. et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from ADA and EASD // Diabetes Care. 2008, 31, 1-11.
4. Уніфікований клінічний протокол надання медичної допомоги хворим на ЦД 2 типу, 2012
5. IDF Clinical GuidelinesTask Force. IDF Global Guidelines for type 2 Diabetes, 2005.
6. UK Prospective Diabetes study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with T2 DM (UKPDS 34) // Lancet. 1998, 352, 854-865.
7. Cusi K., De Fronzo R.A. Metformin: a review of its metabolic effect // Diabetes Rev. 1998, 6, 89-131.
8. The ADVANCE Collaborative Group // Engl. J. Med. 2008, 358, 2560-2572.
9. Amori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis // JAMA. 2007, 298, 194–206.
10. Gerstein H.C. et al. The ORIGIN Study // Am. Heart. J. 2008,155, 26-32.
Downloads
Download data is not yet available.